Why the study?
Does carvedilol reduce microalbuminuria in patients with mild to moderate essential hypertension?
Does carvedilol reduce microalbuminuria in patients with mild to moderate essential hypertension?
Carvedilol may exert a renal protective effect by reducing microalbuminuria independently of blood pressure reduction in patients with essential hypertension.
Carvedilol may confer renal protection via MAU reduction independent of BP effects in essential hypertension; extends evidence for its pleiotropic benefits.
Patients with mild to moderate essential hypertension (n = 1570) were enrolled in a large, multicentre, randomised, open-label study designed to evaluate the safety and efficacy of different regimens of carvedilol. Reported here are the effects of carvedilol on microalbuminuria (MAU) in a subset of 876 patients who underwent MAU assessment (i.e. the Micral-Test) at baseline and at week 12. MAU was present at baseline in 245 (28%) of these patients. Despite different magnitudes of blood pressure reduction, improvements in MAU were similar in all groups (range 54-60%), with complete disappearance occurring in 48-55% of patients. The decrease in MAU did not correlate with the magnitude of blood pressure reduction, suggesting a possible renal protective effect exerted by carvedilol independent of blood pressure reduction mediated by beta-blockade and vasodilatation.
No takes yet. Share an insight, caveat, or question.
Fassbinder et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: